VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$12.33
0.02 (0.16%)
▲
5d:
+1.65%
30d:
+21.72%
90d:
+29.65%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 10.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 10.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.99
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $12.33, which is considered extended relative to its 30-day fair value range of $10.27 to $11.96. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.2) compared to its historical average (14.9). At these levels, the market is pricing in 10.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VMD is in a strong uptrend. The price is approaching resistance at $10.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $11.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VMD is in a strong uptrend. The price is approaching resistance at $10.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $11.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.27 -
$11.96
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 10.8% above Wall St target ($11.00)
- NEUTRAL: Trading at premium valuation - market expects 10.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$10.27 -
$11.96
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.64
(5.2%)
Support & Resistance Levels
Support Level
$9.36
Resistance Level
$10.19
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.21
Wall Street Target
$11.00
(-10.8%)
Revenue Growth (YoY)
27.5%
Profit Margin
5.2%
Valuation Premium vs History
+10.8% premium
PE vs Historical
20.2 vs 14.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.8%
(market-implied from PE analysis)
1-Year Target
$13.66
(+11%)
2-Year Target
$15.14
(+23%)
3-Year Target
$16.77
(+36%)
3-Yr Target (if PE normalizes)
(PE: 20→15)
PE COMPRESSION
$12.36
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 34.1%)
$32.01
(+160%)
Base:
(SPY PE: 20.2, Growth: 34.1%)
$29.71
(+141%)
Bear:
(PE: 14.9, Growth: 34.1%)
$21.90
(+78%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 33.27 | Current EPS (TTM): $0.37
Bull Case
$22.32
(+81%)
Analyst growth 64.9%, PE expands to 36.6
Base Case
$20.29
(+65%)
Market implied 64.9%, PE stable at 33.3
Bear Case
$8.37
(-32%)
Severe decline -20.0%, PE contracts to 28.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Moore
SELL
65000 shares
2026-03-20
Michael Moore
SELL
40232 shares
2026-03-19
Michael Moore
SELL
31570 shares
2026-03-18
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 59 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 62 BUY |
